MA56535A - Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées - Google Patents
Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associéesInfo
- Publication number
- MA56535A MA56535A MA056535A MA56535A MA56535A MA 56535 A MA56535 A MA 56535A MA 056535 A MA056535 A MA 056535A MA 56535 A MA56535 A MA 56535A MA 56535 A MA56535 A MA 56535A
- Authority
- MA
- Morocco
- Prior art keywords
- hbv
- vaccines
- hepatitis
- virus
- self
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962863961P | 2019-06-20 | 2019-06-20 | |
US202063006925P | 2020-04-08 | 2020-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56535A true MA56535A (fr) | 2022-04-27 |
Family
ID=71833364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056535A MA56535A (fr) | 2019-06-20 | 2020-06-19 | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220313815A1 (fr) |
EP (1) | EP3986458A1 (fr) |
AU (1) | AU2020298267A1 (fr) |
CA (1) | CA3143632A1 (fr) |
MA (1) | MA56535A (fr) |
TW (2) | TWI769467B (fr) |
WO (1) | WO2020255055A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
US20230219996A1 (en) * | 2021-07-30 | 2023-07-13 | Arcturus Therapeutics, Inc. | Rna vaccines |
CN115960922A (zh) * | 2021-10-09 | 2023-04-14 | 吴可行 | 自复制rna分子设计及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
LT3243526T (lt) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Rnr pristatymas, skirtas keleto imuninio atsako paleidimui |
JP5940064B2 (ja) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | 低用量のrnaを用いた大型哺乳動物の免疫化 |
JP2014520807A (ja) | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | 免疫原性組成物およびその使用 |
TWI575070B (zh) * | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
JP6881813B2 (ja) | 2014-04-23 | 2021-06-02 | モデルナティーエックス, インコーポレイテッド | 核酸ワクチン |
CA3018223A1 (fr) | 2016-03-28 | 2017-10-05 | Ichor Medical Systems, Inc. | Procede et appareil permettant d'administrer des agents therapeutiques |
CN110073002B (zh) * | 2016-10-17 | 2024-06-11 | 杨森制药公司 | 重组病毒复制子体系及其用途 |
KR102655641B1 (ko) * | 2016-12-05 | 2024-04-05 | 얀센 파마슈티칼즈, 인코포레이티드 | 유전자 발현을 향상시키기 위한 조성물 및 방법 |
GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
AU2018389787A1 (en) * | 2017-12-19 | 2020-06-25 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
CA3086325A1 (fr) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methodes et compositions permettant d'induire une reponse immunitaire contre le virus de l'hepatite b (vhb) |
CA3085492A1 (fr) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methodes et appareil pour l'administration de vaccins contre le virus de l'hepatite b (vhb) |
US20200109178A1 (en) * | 2018-10-08 | 2020-04-09 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
-
2020
- 2020-06-19 US US17/596,874 patent/US20220313815A1/en not_active Abandoned
- 2020-06-19 WO PCT/IB2020/055775 patent/WO2020255055A1/fr active Application Filing
- 2020-06-19 CA CA3143632A patent/CA3143632A1/fr active Pending
- 2020-06-19 TW TW109120795A patent/TWI769467B/zh active
- 2020-06-19 MA MA056535A patent/MA56535A/fr unknown
- 2020-06-19 AU AU2020298267A patent/AU2020298267A1/en not_active Abandoned
- 2020-06-19 TW TW111120040A patent/TWI828168B/zh active
- 2020-06-19 EP EP20746697.0A patent/EP3986458A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202235428A (zh) | 2022-09-16 |
EP3986458A1 (fr) | 2022-04-27 |
US20220313815A1 (en) | 2022-10-06 |
CA3143632A1 (fr) | 2020-12-24 |
TW202108598A (zh) | 2021-03-01 |
TWI769467B (zh) | 2022-07-01 |
WO2020255055A1 (fr) | 2020-12-24 |
AU2020298267A1 (en) | 2022-02-17 |
TWI828168B (zh) | 2024-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56535A (fr) | Molécules d'arn à auto-réplication pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées | |
MA51311A (fr) | Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées | |
MA50520A (fr) | Nouveaux indole-2-carboxamides à substitution pyrazolo-pipéridine hautement actifs agissant contre le virus de l'hépatite b (vhb) | |
MA55321A (fr) | Vaccins à base d'arn contre le vih | |
EP3710049A4 (fr) | Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant les régions pres1 et/ou pres2 et/ou s-hbsag du vhb de la protéine d'enveloppe du vhb | |
HK1248681A1 (zh) | 作為hbsag(hbv表面抗原)和hbv dna生成的抑制劑用於治療乙型肝炎病毒感染的四氫吡啶並嘧啶和四氫吡啶並吡啶類化合物 | |
JOP20170161A1 (ar) | عوامل RNAi للعدوى بفيروس التهاب الكبد ب | |
PH12019500788A1 (en) | Engineered meganucleases specific for recgonition sequences in the hepatitis b virus genome | |
PL1685243T3 (pl) | Unieśmiertelnione ptasie linie komórkowe do wytwarzania wirusów | |
EP3439696A4 (fr) | Vaccin thérapeutique contre le virus de l'hépatite b (vhb) utilisant l'antigène nucléocapsidique du vhb | |
WO2011015656A3 (fr) | Composition pour le traitement d'une infection par le virus de l'hépatite b | |
HRP20090230T1 (en) | Replication-deficient rna viruses as vaccines | |
IL285257A (en) | RNAi materials for hepatitis b virus infection | |
MA56534A (fr) | Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb) | |
MA51312A (fr) | Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb) | |
MA56524A (fr) | Vecteurs d'arénavirus pour vaccins contre le virus de l'hépatite b (vhb) et utilisations associées | |
SG11202005709QA (en) | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines | |
MA50071A (fr) | Polythérapies pour des individus atteints d'une infection au virus de l'hépatite b (vhb) utilisant parapoxvirus ovis (ppvo) et au moins un autre médicament antiviral | |
EP3292202A4 (fr) | Réactifs pour le traitement de l'infection par le virus de l'hépatite b (vhb) et utilisation de ceux-ci | |
IL292625A (en) | Viruses with adapted capsid proteins | |
IL290924A (en) | Vaccines for hepatitis b virus | |
IL287240A (en) | New phenyl and pyridyl urea compounds active against hepatitis b virus (hbv) | |
SG11202111236UA (en) | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) | |
MA56533A (fr) | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 | |
MA56536A (fr) | Administration de nanoparticules lipidiques ou de liposomes de vaccins contre le virus de l'hépatite b (vhb) |